Ohad Hammer - 18 Mar 2026 Form 3 Insider Report for Agomab Therapeutics NV (AGMB)

Role: Director
Signature: /s/ Ellen Lefever, Attorney-in-Fact
Issuer symbol: AGMB
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 16:01:42 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hammer Ohad	Director	AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERPEN, BELGIUM	/s/ Ellen Lefever, Attorney-in-Fact	18 Mar 2026	0002116400

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AGMB	Stock Option (Right to Buy)							18 Mar 2026	Common shares	27,921	$14.26	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2	The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F3	The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

Remarks:

Exhibit 24 - Power of Attorney